Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention
                        and Control

Thomas, Hana; Diamond, Jamie; Vieco, Adrianna; Chaudhuri, Shaoli; Shinnar, Eliezer; Cromer, Sara J.; Perel, Pablo; Mensah, George A.; Narula, Jagat; Johnson, Catherine O.; Roth, Gregory A.; Moran, Andrew E.

doi:10.1016/j.gheart.2018.09.511

Cited by 315 publications

(236 citation statements)

References 32 publications

Supporting

Mentioning

210

Contrasting

Unclassified

Order By: Relevance

“…The need for novel diagnostic and prognostic biomarkers that can aid both the prevention and the treatment of CVD is therefore pressing. This review will mainly focus on acute coronary syndromes since findings continue to accumulate showing that heart attack and coronary artery disease, in general, are the most common causes of CVD deaths in both male and female patients [195].…”

Section: Mirnas In Cardiovascular Diseasementioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

919

583

View full text Add to dashboard Cite

MicroRNAs (miRNAs) represent a class of small, non-coding RNAs with the main roles of regulating mRNA through its degradation and adjusting protein levels. In recent years, extraordinary progress has been made in terms of identifying the origin and exact functions of miRNA, focusing on their potential use in both the research and the clinical field. This review aims at improving the current understanding of these molecules and their applicability in the medical field. A thorough analysis of the literature consulting resources available in online databases such as NCBI, PubMed, Medline, ScienceDirect, and UpToDate was performed. There is promising evidence that in spite of the lack of standardized protocols regarding the use of miRNAs in current clinical practice, they constitute a reliable tool for future use. These molecules meet most of the required criteria for being an ideal biomarker, such as accessibility, high specificity, and sensitivity. Despite present limitations, miRNAs as biomarkers for various conditions remain an impressive research field. As current techniques evolve, we anticipate that miRNAs will become a routine approach in the development of personalized patient profiles, thus permitting more specific therapeutic interventions.Biogenesis of miRNA begins in the nucleus, where the transcription of its precursor, primary miRNA or pri-miRNA takes place under the influence of RNA polymerases II and III [11,12]. The resulting molecule is a hairpin-like structure, which contains a loop at one end [11]. This primordial mi-RNA precursor that is usually made up of hundreds of nucleotides is then processed consecutively by two RNase III enzymes [13][14][15]. The first enzyme to act upon the pri-miRNA, which still resides in the nucleus, is called Drosha or DCGR8, and turns it into a new hairpin-like structure of approximately 70 nucleotides, the Precursor-miRNA or pre-miRNA. The latter is then transported to the cytoplasm, with the help of Exportin-5, where it is cleaved again by the Ago2/Dicer complex leading to the short, mature miRNA double strands [16].Further on, one of the strands, usually known as the guide strand, will be integrated into the RNA-induced silencing complex (RISC), while the other one, known as the passenger strand, is going to be degraded, even though in some occasions it has been found to be also functional [17]. In most cases, the strand that contains the less stable 5 end or a uracil at the beginning is more likely to be selected as the guide strand [18][19][20]. In those situations, where the passenger strand is not degraded and both get incorporated into the miRISC complex, the mature miRNA in the guide strand will be the dominant one [21,22].The main role of miRNA in the human body is gene regulation [23] by mediating the degradation of mRNA and also by regulating transcription and translation through canonical and non-canonical mechanisms [4]. The canonical mechanism means that the miRISC complex containing the miRNA guide strand is exerting its action by binding to the targ...

show abstract

Section: Mirnas In Cardiovascular Diseasementioning

confidence: 99%

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Condrat

Thompson

Barbu

et al. 2020

Cells

919

583

View full text Add to dashboard Cite

show abstract

“…Following the finalisation of the data collection form, data recruitment commenced in September 2017. Potential participants were patients who underwent PCI at VNHI during the study period and met the following criteria: (1) Vietnamese residents aged 18 years and over; (2) Had at least one active phone contact number; and (3) Able to communicate, understand the information sheet and did not opt-out of future follow-ups by the time of discharge. There were no exclusion criteria.…”

Section: Data Collectionmentioning

confidence: 99%

“…If we use an average monthly income of a nurse at VNHI, which is approximately 1066 USD 1 [24], then the estimated time-cost of baseline data collection for one case, which is the income of hospital nurse in 1 hour, was equivalent to 1066/(30*8) = 4.4 USD. 2 In follow-up survey, approximate 15-30 minutes (phone or direct interviews) will be required for each patient, which was roughly equivalent to 1.1-2.2 USD. d) The level of support from patients, clinical staff and the leader team.…”

Section: Registry Viabilitymentioning

confidence: 99%

“…Coronary heart disease (CHD) is consistently the leading cause of death worldwide, responsible for approximately 16.6% of total deaths in 2016 and places a large economic burden on the population [1,2]. Since its inception in 1977, percutaneous coronary intervention (PCI) has been recognised as a valuable procedure for treating CHD patients and has become a common part of routine practice worldwide [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Conclusions: The proposed methodology for establishing a PCI registry in a large hospital in Vietnam produced high quality data and was considered worthwhile by hospital staff. The model has the potential opportunity for replication in other cardiac catheterisation sites, leading to a national PCI registry in Vietnam.Coronary heart disease (CHD) is consistently the leading cause of death worldwide, responsible for approximately 16.6% of total deaths in 2016 and places a large economic burden on the population [1,2]. Since its inception in 1977, percutaneous coronary intervention (PCI) has been recognised as a valuable procedure for treating CHD patients and has become a common part of routine practice worldwide [3,4].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Establishment of a Percutaneous Coronary Intervention Registry in Vietnam: Rationale and Methodology

Nguyen²,

Pham³

et al. 2020

View full text Add to dashboard Cite

Background:In lower-and middle-income countries across Asia there has been a rapid expansion and uptake of percutaneous coronary intervention (PCI). However, there has been limited routine collection of related data, particularly around quality, safety and cost. The aim of this study was to assess the viability of implementing routine collection of PCI data in a registry at a leading hospital in Hanoi, Vietnam. Method: A Vietnamese data collection form and collection strategy were developed in collaboration with the Vietnam National Heart Institute. Information on patient characteristics, treatments, and outcomes was collected through direct interviews using a standardised form and medical record abstraction, while PCI data was read and coded into paper forms by interventional cardiologists. Viability of the registry was determined by four main factors: 1) being able to collect a representative sample; 2) quality of data obtained; 3) costs and time taken for data collection by hospital staff; and 4) level of support from key stakeholders in the institute. Results: Between September 2017 and May 2018, 1,022 patients undergoing PCI were recruited from a total of 1,041 procedures conducted during that time frame. The estimated mean time to collect information from patients before discharge was 60 minutes. Of the collected data fields, 98% were successfully completed. Most hospital staff surveyed indicated support for the continuation of the activity following the implementation of the pilot study. Conclusions: The proposed methodology for establishing a PCI registry in a large hospital in Vietnam produced high quality data and was considered worthwhile by hospital staff. The model has the potential opportunity for replication in other cardiac catheterisation sites, leading to a national PCI registry in Vietnam.Coronary heart disease (CHD) is consistently the leading cause of death worldwide, responsible for approximately 16.6% of total deaths in 2016 and places a large economic burden on the population [1,2]. Since its inception in 1977, percutaneous coronary intervention (PCI) has been recognised as a valuable procedure for treating CHD patients and has become a common part of routine practice worldwide [3,4]. The Asia-Pacific region is home to nearly 60% of the world's population, where CHD is now a leading cause of mortality [5,6] and the development of PCI registries is of growing interest [7][8][9]. As a clinical quality registry, a PCI Education in Therapeutics. He is a cardiovascular epidemiologist and clinical trialist with a specific interest in quality improvement and outcomes research. He holds a NHMRC Senior Research Fellowship and has had continual NHMRC research funding since 1997. He has published more than 250 papers with over 6785 citations (Google Scholar H-index 41). Over the past 5 years (from 2009), he has received 17 peer reviewed grants as a Chief Investigator from National and International funding agencies totalling over $70M.

show abstract

A Novel Anti‐Coagulative Nanocomplex in Delivering miRNA‐1 Inhibitor Against Microvascular Obstruction of Myocardial Infarction

Hong

Wei

Xue

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Great progress has been made in miRNA nanodelivery for the treatment of myocardial infarction (MI). However, miRNA nanodelivery within the infarct is impeded by microvascular obstruction as a local circulatory disorder caused by microthrombus formation in microvessels. Knowing that low molecular weight heparin (LMWH) can effectively prevent microthrombus formation in microcirculation, it is hypothesized whether surface modification of the nanocarrier with LMWH can overcome microvascular obstruction in the infarct area for better miRNA delivery. Herein, a novel nanocomlex consisting of dendrigraft poly‐l‐lysine (DGL)‐loaded miR‐1 inhibitor as the core to decrease apoptosis of cardiomyocytes and LMWH as the shell to overcome microvascular obstruction of the infarct area is developed. The results show that this anti‐coagulative nanocomlex is able to reduce microthrombus formation in microvessels and inhibit blood‐coagulation factor Xa, thereby overcoming microvascular obstruction in the infarct area. In addition, it further enhances the uptake of miR‐1 inhibitor within the infarct and decreases myocardiocyte apoptosis, thus improving the cardiac function and attenuating the myocardial fibrosis. In conclusion, modification of DGL‐loaded miR‐1 inhibitor with LMWH helps overcome microvascular obstruction in delivering the drug to the infarct area, thus providing a promising therapeutic strategy for achieving a better therapeutic outcome of MI.

show abstract

Global Atlas of Cardiovascular Disease 2000-2016: The Path to Prevention and Control

Cited by 315 publications

References 32 publications

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis

Establishment of a Percutaneous Coronary Intervention Registry in Vietnam: Rationale and Methodology

A Novel Anti‐Coagulative Nanocomplex in Delivering miRNA‐1 Inhibitor Against Microvascular Obstruction of Myocardial Infarction

Contact Info

Product

Resources

About